Xintela AB’s annual report 2021 published

Xintela AB (publ) has today published its annual report for 2021 on the website www.xintela.se. The annual report is available today in Swedish and an English version will be published shortly. The report is available under financial reports. The financial year refers to the period 1 January – 31 December 2021. The Swedish version of […]

Targinta presents new preclinical data on TARG10 at the AACR Annual Meeting

The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), presents new preclinical data on TARG10 at the AACR Annual Meeting (April 8-13) in a poster titled “The integrin α10β1 antibody TARG10 reduces tumor growth and metastasis of triple-negative breast cancer”. Targinta develops first-in-class tumor-targeting antibodies and ADCs against the novel and patent […]

NOTICE OF ANNUAL GENERAL MEETING IN XINTELA AB (PUBL)

The shareholders of Xintela AB (publ) are invited to the annual general meeting on Friday, May 6 2022, at 09.00 CET at Medicon Village, Scheeletorget 1, Building 601 Lund, Sweden. The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. […]

Targinta selects ADC-antibody TARG9 as drug candidate

The oncology company Targinta AB, a wholly owned subsidiary of Xintela AB (publ), today announces the selection of the drug candidate TARG9, a conjugated antibody, or ADC (antibody-drug conjugate), targeting the cancer marker integrin α10β1. The candidate, being developed against triple-negative breast cancer and glioblastoma, now enters preclinical development. TARG9 consists of an integrin α10-antibody […]

Xintela starts clinical study of XSTEM® in knee osteoarthritis

Xintela starts its first-in-human study (Phase I/IIa) with XSTEM® for the treatment of knee osteoarthritis in Australia. XSTEM, which consists of allogeneic (donated) integrin alpha10beta1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Patients with moderate knee osteoarthritis (grade II-III) will receive a single injection of XSTEM into the knee joint. Three different doses […]

Xintela AB Year-end report January – December 2021

Summary of the year end report. The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Fourth quarter October 1 – December 31, 2021Income amounted to TSEK 0 (0).Loss before tax totalled TSEK 26,643 (loss: 25,335).Loss per share* was SEK 0.30 (loss: 0.34).At December 31, 2021, the equity/assets ratio** was 16% (57). […]

Xintela granted 4.8 million SEK from Vinnova

Lund, Sweden, January 18, 2022 – Xintela has been granted SEK 4.8 million from Vinnova within the call “New and improved biological drugs in healthcare”. The grant will support a clinical phase I/IIa study to evaluate Xintela’s stem cell product XSTEM® for the treatment of patients with difficult-to-heal leg ulcers. The project, which will be […]

Xintela newsletter January 2022

Dear shareholders, I would like to wish you all a Happy New Year, briefly summarize the past year for Xintela and its subsidiary Targinta, and focus on some important upcoming events that we are looking forward to in 2022. It has been a fantastic and eventful year for our companies with, among other things, an […]

Xintela and ScanVet Animal Health A/S sign Letter of Intent

Xintela announces today that the company has signed a Letter of Intent with the Danish animal health company ScanVet Animal Health A/S. The parties intend to enter into an agreement to develop, market and sell EQSTEM®, Xintela’s proprietary equine stem cell product, for the treatment of joint diseases including osteoarthritis. Under the Letter of Intent, […]